Photodynamic Therapy system with singlet 02 Dosimetry
Award last edited on: 6/5/02

Sponsored Program
Awarding Agency
Total Award Amount
Award Phase
Solicitation Topic Code

Principal Investigator
Martin G Cohen

Company Information

Quantronix Corporation

41 Research Way
East Setauket, NY 11733
   (631) 784-6100
Location: Single
Congr. District: 01
County: Suffolk

Phase I

Contract Number: 1R43CA045093-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
Phase I Amount
A system for photodynamic therapy (PDT) that provides, in addition to the therapeutic light dose, a method of real-time, intraoperative dosimetry will be assembled and demonstrated. In PDT, a parenterally administered photoactive dye (dihematoporphyrin ether, DHE) localizes in malignant tissue. Subsequent irradiation of the DHE-bearing tissue with light (630 nm) produces, in combination with oxygen, the cytotoxic reaction product, singlet oxygen (102). By monitoring the real-time-resolved 102 fluorescence at 1.27 nm, a signal proportional to the 102 production rate will result, thereby providing dosimetry information.The system to be demonstrated employs a CW-pumped, Q-switched, frequency-doubled YAG laser driving a tunable dye laser emitting 70nanosecond, 630-nanometer wavelength pulses at a 10-KHz rate. In addition to providing realtime dosimetry information, the system also allows for the study of a possible increase in the therapeutic effect due to the generation of the cytotoxic agent 102 in "bursts." To date, the reciprocity of the PDT light dose does not appear to have been thoroughly investigated.Finally, the inherent wavelength agility of a tunable dye laser makes this system useful with new photoactive dyes operating beyond 630 nm.National Cancer Institute (NCI)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
Phase II Amount